# Cardiovascular Risk Determinants in Euthyroid Patients with Obesity: The Strange Case of TSH in Primary Prevention

**Authors:** Cristina Vassalle, Luisella Vigna, Paolo Piaggi, Marco Scalese, Laura Sabatino, Francesca Mastorci, Gabriele Trivellini, Filomena Napolitano, Francesca Gori, Alessandra Piontini, Alessandro Pingitore

PMC · DOI: 10.3390/jcm15041427 · 2026-02-11

## TL;DR

This study explores how TSH levels relate to cardiovascular risk in euthyroid individuals with obesity, finding that higher TSH is linked to severe obesity and certain risk factors, but not directly to overall cardiovascular risk scores.

## Contribution

The study identifies specific determinants of TSH levels in euthyroid individuals with obesity and highlights the complex relationship between TSH and cardiovascular risk.

## Key findings

- Higher TSH levels in euthyroid individuals correlate with severe obesity and insulin resistance.
- Female gender, HOMA-IR, and AST are independent determinants of TSH in those with high cardiovascular risk.
- TSH levels are not directly associated with the ASCVD risk score despite being linked to obesity and metabolic factors.

## Abstract

Background: Thyrotropin (TSH), even in the normal range, is associated with components of cardiometabolic syndrome. We aimed to assess the relation between TSH and cardiovascular (CV) risk in euthyroid patients with overweight/obesity without previous cardiac events. Methods: A total of 1588 subjects (1132 females, mean age 53 ± 14 years) were recruited. This was an observational study. TSH, body mass index, waist circumference (WC), creatinine, hepatic enzymes, homocysteine, C reactive protein, glycated hemoglobin, homeostatic model assessment for insulin resistance (HOMA-IR), basal and 2 h glucose and insulin, fibrinogen, uric acid, a complete blood count, a complete lipid profile, and blood pressure were measured in all subjects. The Atherosclerotic Cardiovascular Disease (ASCVD) risk score was calculated. Results: More severe degrees of obesity were associated with higher TSH quartiles; specifically, 33% of subjects with grade III obesity had TSH in the 75th percentile. Multiple regression showed that female gender (t-value 3.6, p < 0.001), HOMA-IR (1.9, ≤0.05) and aspartate transaminase (AST; 2.8, <0.01) represent independent determinant factors affecting TSH levels in the population at higher CV risk (intermediate–high ASCVD risk score > 7.5%; n = 709). Similarly, TSH determinants in subjects with central obesity (n = 1197, WC >102 cm males, >88 cm females) were female gender (2.2, <0.05), HOMA-IR (2.7, <0.01) and smoking habit (−2.3, <0.5). Moreover, there was no significant relationship between TSH and ASCVD risk score. Conclusions: Higher TSH levels in the euthyroid range are related to high degrees of obesity and some CV risk factors, in subjects at higher cardiometabolic risk; however, for the different weight and sign of CV determinants (e.g., smoking habit) on the TSH system, the ASCVD risk score cannot evidence this relationship.

## Linked entities

- **Diseases:** obesity (MONDO:0011122), cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, DIO1 (iodothyronine deiodinase 1) [NCBI Gene 1733] {aka 5DI, THMA2, TXDI1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, DIO2 (iodothyronine deiodinase 2) [NCBI Gene 1734] {aka 5DII, D2, DIOII, SELENOY, SelY, TXDI2}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, TRH (thyrotropin releasing hormone) [NCBI Gene 7200] {aka Pro-TRH, TRF}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** liver fibrosis (MESH:D008103), weight loss (MESH:D015431), Insulin resistance (MESH:D007333), myocardial infarction (MESH:D009203), CV (MESH:D002318), diabetes (MESH:D003920), malignancy (MESH:D009369), Euthyroid (MESH:D005067), hypertension (MESH:D006973), III (MESH:C537189), dyslipidemia (MESH:D050171), hypothyroidism (MESH:D007037), coronary heart disease (MESH:D003327), ASCVD (MESH:D050197), disease (MESH:D004194), injury to (MESH:D014947), liver disease (MESH:D008107), inflammatory (MESH:D007249), MS (MESH:D024821), grade I, II and III (MESH:D001254), abdominal obesity (MESH:D056128), metabolic dysfunction (MESH:D008659), blood hypercoagulability (MESH:D019851), Overweight (MESH:D050177), stroke (MESH:D020521), cardiac disease (MESH:D006331), hyperthyroidism (MESH:D006980), underweight (MESH:D013851), thyroid autoimmunity (MESH:D013967), thyroid diseases (MESH:D013959), Obesity (MESH:D009765)
- **Chemicals:** TG (MESH:D014280), thiocyanate (MESH:C031760), fatty acid (MESH:D005227), estradiol (MESH:D004958), EDTA (MESH:D004492), uric acid (MESH:D014527), homocysteine (MESH:D006710), sodium citrate (MESH:D000077559), 2hINS (-), L-T4 (MESH:D013974), Thyrotropin (MESH:D013972), glucose (MESH:D005947), creatinine (MESH:D003404), Cholesterol (MESH:D002784), Blood glucose (MESH:D001786), INS (MESH:D007328), T3 (MESH:D014284), lipid (MESH:D008055), glycogen (MESH:D006003), sodium fluoride (MESH:D012969)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12941703